6.19
price up icon0.49%   0.03
pre-market  プレマーケット:  6.06   -0.13   -2.10%
loading
前日終値:
$6.16
開ける:
$6.24
24時間の取引高:
267.83K
Relative Volume:
0.89
時価総額:
$277.24M
収益:
$84.82M
当期純損益:
$-21.43M
株価収益率:
-12.63
EPS:
-0.49
ネットキャッシュフロー:
$-27.23M
1週間 パフォーマンス:
-2.21%
1か月 パフォーマンス:
-25.24%
6か月 パフォーマンス:
-46.59%
1年 パフォーマンス:
-34.01%
1日の値動き範囲:
Value
$6.11
$6.35
1週間の範囲:
Value
$6.05
$6.81
52週間の値動き範囲:
Value
$6.01
$20.90

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
名前
Y Mabs Therapeutics Inc
Name
セクター
Healthcare (1176)
Name
電話
212-847-9841
Name
住所
230 PARK AVENUE, NEW YORK, NY
Name
職員
100
Name
Twitter
Name
次回の収益日
2024-11-08
Name
最新のSEC提出書
Name
YMAB's Discussions on Twitter

YMAB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
6.19 277.24M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
427.89 110.19B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
687.80 75.58B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
647.39 38.71B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
264.99 34.18B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
117.25 28.11B 3.30B -501.07M 1.03B -2.1146

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-11-18 開始されました Oppenheimer Outperform
2024-08-16 開始されました Cantor Fitzgerald Overweight
2024-06-28 開始されました Truist Buy
2023-05-10 アップグレード Wedbush Neutral → Outperform
2023-04-03 ダウングレード Guggenheim Buy → Neutral
2023-01-27 ダウングレード Morgan Stanley Equal-Weight → Underweight
2023-01-05 ダウングレード Cowen Outperform → Market Perform
2022-12-02 ダウングレード BofA Securities Buy → Neutral
2022-10-31 ダウングレード JP Morgan Neutral → Underweight
2022-10-31 ダウングレード Wedbush Outperform → Neutral
2022-07-06 再開されました Canaccord Genuity Buy
2022-06-24 開始されました BMO Capital Markets Outperform
2022-02-03 再開されました Guggenheim Buy
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-11-16 ダウングレード JP Morgan Overweight → Neutral
2021-05-07 アップグレード BofA Securities Neutral → Buy
2021-04-23 再開されました Cowen Outperform
2021-03-22 再開されました JP Morgan Overweight
2021-01-15 ダウングレード BofA Securities Buy → Neutral
2020-11-09 繰り返されました H.C. Wainwright Buy
2020-05-05 開始されました Barclays Overweight
2020-05-01 開始されました Janney Buy
2020-04-29 開始されました Morgan Stanley Equal-Weight
2019-12-24 開始されました JP Morgan Overweight
2019-11-20 開始されました Guggenheim Buy
2019-09-04 開始されました Wedbush Outperform
2019-04-01 開始されました H.C. Wainwright Buy
2018-10-16 開始されました BTIG Research Buy
2018-10-16 開始されました BofA/Merrill Buy
すべてを表示

Y Mabs Therapeutics Inc (YMAB) 最新ニュース

pulisher
Jan 20, 2025

Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace

Jan 17, 2025
pulisher
Jan 15, 2025

Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jan 15, 2025
pulisher
Jan 15, 2025

Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World

Jan 12, 2025
pulisher
Jan 12, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance

Jan 11, 2025
pulisher
Jan 10, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet - Simply Wall St

Jan 10, 2025
pulisher
Jan 10, 2025

Correcting & ReplacingY-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth - StockTitan

Jan 10, 2025
pulisher
Jan 10, 2025

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - Business Upturn

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Therapeutics, Inc. Announces Executive Changes - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Appoints Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit - citybiz

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Strengthens DANYELZA Team with Industry Veteran Doug Gentilcore as Business Unit Head - StockTitan

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Therapeutics Hits $88M Revenue Target, Unveils Strategic Split Into Two Business Units - StockTitan

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Buy” by Analysts - Defense World

Jan 10, 2025
pulisher
Jan 10, 2025

Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89 - MarketBeat

Jan 10, 2025
pulisher
Jan 08, 2025

Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA - Yahoo Finance

Jan 08, 2025
pulisher
Jan 08, 2025

When (YMAB) Moves Investors should Listen - Stock Traders Daily

Jan 08, 2025
pulisher
Jan 07, 2025

Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jan 07, 2025
pulisher
Jan 01, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Geode Capital Management LLC - Defense World

Jan 01, 2025
pulisher
Dec 31, 2024

Barclays PLC Purchases 56,244 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Dec 31, 2024
pulisher
Dec 28, 2024

(YMAB) Trading Report - Stock Traders Daily

Dec 28, 2024
pulisher
Dec 25, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by State Street Corp - Defense World

Dec 25, 2024
pulisher
Dec 25, 2024

State Street Corp Grows Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat

Dec 25, 2024
pulisher
Dec 23, 2024

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times

Dec 23, 2024
pulisher
Dec 23, 2024

Y-mAbs Therapeutics to Present at J.P. Morgan Healthcare Conference 2025: Cancer Treatment Innovation Spotlight - StockTitan

Dec 23, 2024
pulisher
Dec 21, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Dec 21, 2024
pulisher
Dec 20, 2024

We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely - Yahoo Finance

Dec 20, 2024
pulisher
Dec 18, 2024

(YMAB) Trading Signals - Stock Traders Daily

Dec 18, 2024
pulisher
Dec 17, 2024

Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Australia

Dec 17, 2024
pulisher
Dec 16, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Dec 16, 2024
pulisher
Dec 16, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Rating of “Buy” by Brokerages - Defense World

Dec 16, 2024
pulisher
Dec 15, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Bought by Charles Schwab Investment Management Inc. - Defense World

Dec 15, 2024
pulisher
Dec 13, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Earns “Buy” Rating from HC Wainwright - Defense World

Dec 13, 2024
pulisher
Dec 11, 2024

Y-mAbs Therapeutics (NASDAQ:YMAB) Receives "Buy" Rating from HC Wainwright - MarketBeat

Dec 11, 2024
pulisher
Dec 11, 2024

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by Point72 Asset Management L.P. - MarketBeat

Dec 11, 2024
pulisher
Dec 10, 2024

We Think Y-mAbs Therapeutics (NASDAQ:YMAB) Can Afford To Drive Business Growth - Simply Wall St

Dec 10, 2024
pulisher
Dec 09, 2024

Equities Analysts Offer Predictions for YMAB FY2024 Earnings - MarketBeat

Dec 09, 2024
pulisher
Dec 09, 2024

Brookline Capital Management Predicts YMAB FY2024 Earnings - Defense World

Dec 09, 2024
pulisher
Dec 08, 2024

Intech Investment Management LLC Invests $133,000 in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Dec 08, 2024
pulisher
Dec 07, 2024

Trend Tracker for (YMAB) - Stock Traders Daily

Dec 07, 2024
pulisher
Dec 07, 2024

Y-mAbs' CD38-SADA Shows Promising Anti-Tumor Results in NHL Treatment at ASH Meeting - StockTitan

Dec 07, 2024
pulisher
Dec 06, 2024

United Rentals (URI-N) QuotePress Release - The Globe and Mail

Dec 06, 2024
pulisher
Dec 06, 2024

Brookline Capital Initiates Coverage of Y-mAbs Therapeutics (YMAB) with Buy Recommendation - MSN

Dec 06, 2024

Y Mabs Therapeutics Inc (YMAB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$21.80
price up icon 4.81%
$73.47
price up icon 2.14%
$22.10
price up icon 16.13%
$367.97
price up icon 2.52%
biotechnology ONC
$218.70
price up icon 4.10%
$117.25
price up icon 4.75%
大文字化:     |  ボリューム (24 時間):